Cydan, an orphan-drug accelerator bankrolled by New Enterprise Associates and Pfizer Ventures, has secured another $10 million in venture cash. That brings its total haul to $26 million since its April launch, money the company will use scout for assets and fund new companies focused on rare disease. News